The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Activity of the FcRH5 bispecific antibody cevostamab after prior BCMA therapy in multiple myeloma
Alexander Lesokhin, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the activity of the FcRH5-targeting bispecific antibody cevostamab in patients with multiple myeloma previously treated with BCMA-directed therapies. He notes that responses appear more frequent after prior CAR T-cell therapy than after BCMA-directed bispecific antibodies, potentially reflecting differences in treatment sequencing, immune recovery, and T-cell exhaustion, though these observations remain exploratory. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There has been a study looking at cevostamab use following BCMA-directed therapy. It was a fairly, you know, small sample size there, but among patients that had received prior BCMA-directed bispecific therapy, you know, responses were observed, but, you know, a fairly low response rate was observed. Among individuals that had prior CAR T cell therapy, response rates were definitely seen and they were higher...
There has been a study looking at cevostamab use following BCMA-directed therapy. It was a fairly, you know, small sample size there, but among patients that had received prior BCMA-directed bispecific therapy, you know, responses were observed, but, you know, a fairly low response rate was observed. Among individuals that had prior CAR T cell therapy, response rates were definitely seen and they were higher. I think the take-home message here, or I think the nuance here, is that, you know, we traditionally treat with BCMA-directed bispecifics until progression, whereas CAR T cell therapy is given as, you know, sort of a single dose and done. So there’s time for immune recovery following CAR T, whereas there’s, you know, less time following bispecifics. So I think the question you’re asking is difficult to answer because after CAR T, we do see responses. So it does appear that’s a little bit speculative. It’s very difficult to truly answer that question.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
